Compounded GLP-1 is exclusively 503A, meaning it remains subject to state pharmacy board review and patient-centric quality oversight, not commercial FDA approval pathways that might shift
Studies show that when patients stop semaglutide, weight regain occurs gradually over 612 months, suggesting the medication works best as an ongoing treatment rather than a fixed course
TL;DR Jardiance (empagliflozin) is SGLT2 inhibitor taken as daily oral medication, best for heart failure and chronic kidney disease protection Ozempic (semaglutide) is GLP 1 receptor agonist administered as once weekly injection, superior for weight loss (up to 15% body weight) and A1C reduction (up to 1.8%) Both are approved diabetes medications that help manage blood sugar levels and provide cardiovascular benefits Jardiance reduces risk of cardiovascular death by 38% in patients with established cardiovascular disease while Ozempic reduces major cardiovascular events like heart attacks and strokes by 26% Jardiance costs $144 monthly versus Ozempics $329.95
That's because, unlike a traditional savings account, HSAs offer the ability to invest the deposits in mutual funds, index funds, ETFs and other growth investments, potentially earning valuable returns that are being saved tax-free
Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality
